Results from research conducted by scientists at Pfizer for a new method for residual active pharmaceutical ingredient (API) analysis have recently been published in a case study by Phenomenex.
Results from research conducted by scientists at Pfizer for a new method for residual active pharmaceutical ingredient (API) analysis have recently been published in a case study by Phenomenex. The new method replaces 16 individual analyses and has reportedly provided cost savings of £320,000 (more than $516,000) per year. The method requires just one UHPLC instrument using Phenomenex’s Kinetex 1.7 micron core-shell columns to resolve all 16 ingredients in 6 minutes. It uses less solvent, reduces waste disposal costs and frees up laboratory time.
"High-volume laboratories, such as those in pharmaceutical QC, have an acute need to reduce operating costs and free up resources," explains Jeremy Bierman, brand manager for HPLC products. "The Kinetex core-shell technology allows the development of faster and more efficient analytical methods to deliver significant cost and time savings."The method can be reviewed and/or downloaded atwww.phenomenex.com/info/form/casestudy
Green Chemistry: What is it (and What Is It Not)? And How Does It Apply to Gas Chromatography?
October 31st 2024Everyone is talking about sustainability, and organizations are creating sustainability programs. But what does green chemistry really mean, and how does it apply to gas chromatography?
A Review of the Latest Separation Science Research in PFAS Analysis
October 17th 2024This review aims to provide a summary of the most current analytical techniques and their applications in per- and polyfluoroalkyl substances (PFAS) research, contributing to the ongoing efforts to monitor and mitigate PFAS contamination.